Halberd Corp (HALB)

[solidgold]

Halberd Corp. CEO Interviewed on Money TV; Discusses 2020 Accomplishments and Plans
Press Release | 11/25/2020

JACKSON CENTER, PA / ACCESSWIRE / November 25, 2020 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV. Mr. Hartman recapped the company's accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future.

Mr. Hartman detailed some of the most recent developments in Halberd's top priority research: to develop products which should facilitate diagnostic, prevention and treatment of Covid-19. This includes:

Three issued patents;
Six provisional patent applications;
Two unique Covid-19 antibodies;
Nasal spray preventative alternative to Covid-19 vaccine (under development);
Patent-pending fluorescent antibody for rapid Covid-19 diagnostic test (under development).


Mr. Hartman also explained the plans to fund its R&D through a Section 501(c)(3) charitable organization, and/or through one or more joint ventures with established pharmaceutical companies to expedite Halberd's products to market.

Future plans include possible listing the company on foreign stock markets utilizing foreign subsidiaries, such as the one currently established in the UK.

You can view the entire interview video here.

https://halberdcorporation.com/wp-content/uploads/2020/11/MoneyTV-24-Nov-20.mp4
If you would like to be added to our email subscriber list, click here and submit the form.

For more information please contact:
William A. Hartman
[e-mail]
[e-mail]
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC

About Halberd Corporation.
Halberd Corporation. (OTC PINK:HALB), is a publicly-traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," and, "Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans," "Nasal Spray to Prevent the Transmission of Covid-19," and "Method For Treating And Curing Covid-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus." Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.